Anchiano Therapeutics has poached David Kerstein from Takeda’s senior team as its new Chief Medical Officer.
At Takeda, Mr Kerstein served as Senior Medical Director of Oncology Clinical Research where he was the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib.
He is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.
“We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,” said Frank Haluska, President and CEO of Anchiano Therapeutics.
Mr Kerstein added: “I am eager to contribute to Anchiano’s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder.”